Recombinant Human TFF2 Protein (Gln24-Tyr129), C-His tagged

• Cat.No.: TFF2-6419H
• Product Overview: Recombinant human TFF2 (Gln24-Tyr129) fused with the C-terminal His tag was expressed in mammalian cells.

Specification

• Source: Mammalian cells
• Species: Human
• Tag: C-His
• Form: Lyophilized powder/frozen liquid
• Molecular Mass: 11.66 kDa
• Protein Length: Gln24-Tyr129
• Purity: > 90 % as determined by SDS-PAGE
• Notes: For research use only.
• Storage: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 centigrade for one week. Store at -20 to -80 centigrade for twelve months from the date of receipt.
• Storage Buffer: Supplied as solution form in PBS or lyophilized from PBS.
• Reconstitution: Reconstitute in sterile water for a stock solution.
• Shipping: They are shipped out with dry ice/blue ice unless customers require otherwise.

Gene Information

• Gene Name: TFF2 trefoil factor 2 [ Homo sapiens (human) ]
• Official Symbol: TFF2
• Synonyms: TFF2; trefoil factor 2; SML1, spasmolytic protein 1; spasmolysin; spasmolytic protein 1; spasmolytic polypeptide; SP; SML1
• Gene ID: 7032
• mRNA Refseq: NM_005423
• Protein Refseq: NP_005414
• MIM: 182590
• UniProt ID: Q03403

Reviews

03/14/2020

The manufacturer's technical support can also aid researchers in the data analysis phase.

12/17/2018

the manufacturer's technical support is instrumental in assisting researchers throughout their trials.

04/15/2016

They can provide valuable guidance in experimental design, optimization, and troubleshooting, helping researchers overcome challenges and maximize the efficiency of their trials.

Q&As

How does TFF2 protein contribute to the protection of the gastric mucosa?

TFF2 promotes the formation of a protective mucous layer on the stomach lining, preventing damage from stomach acid and other harmful factors.

Can TFF2 protein be administered orally for clinical applications?

Researchers are exploring various methods of delivering TFF2 protein, including oral administration, to treat gastrointestinal conditions.

In what ways is TFF2 protein being studied for potential therapeutic applications in IBD?

TFF2 is being investigated for its potential to reduce inflammation and promote mucosal healing in IBD patients.

Are there ongoing clinical trials or research investigating the therapeutic potential of TFF2 protein?

Yes, there are ongoing studies exploring the use of TFF2 protein in the treatment of various gastrointestinal disorders.

How does TFF2 protein compare to other treatments for gastric ulcers or IBD?

TFF2 protein-based therapies may offer an alternative or complementary approach to traditional treatments for these conditions.